Skip to content
SpectraWAVE, Inc.
  • Home
  • Product
  • About Us
  • News
  • Contact
SpectraWAVE, Inc.
  • Home
  • Product
  • About Us
  • News
  • Contact

Uncategorized

SpectraWAVE Appoints Brad Davis as Chief Commercial Officer and Bill Kelly as Chief Financial Officer

January 9, 2025
Go To Article

SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System

September 11, 2024
Go To Article

SpectraWAVE Secures 510(k) Clearance to Add Saline Imaging and Expanded Artificial Intelligence Features to the HyperVue™ Imaging System

September 19, 2023
Go To Article

SpectraWAVE Secures 510(k) Clearance of HyperVue™ Intravascular Imaging System

March 1, 2023
Go To Article
Older Posts »

SpectraWAVE
12 Oak Park Drive Bedford, MA 01730 US
855-DEEP-OCT     info@spectrawave.com

  • LinkedIn
  • Twitter
  • Home
  • Product
  • About Us
  • News
  • Contact
Indications for Use
The HyperVue Imaging System is intended for the imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures.
The Starlight Imaging Catheter is intended for use in vessels 2.0 to 5.2 mm in diameter.
The Starlight Imaging Catheter is not intended for use in a target vessel which has undergone a previous bypass procedure.
The NIRS capability of the HyperVue Imaging System is intended for the detection of lipid-core containing plaques of interest.
The NIRS capability of the HyperVue Imaging System is intended for the assessment of coronary artery lipid core burden.
The NIRS capability of the HyperVue Imaging System is intended for the identification of patients and plaques at increased risk of major adverse cardiac events.

© 2023 SpectraWAVE. All rights reserved. HyperVue, Starlight, and DeepOCT are commercial trademarks for the SpectraWAVE Imaging System, Catheter, and Image cleared for sale in the U.S.A.
900027 rev. 4 ​